# Phase II Study of QLC2519 in Pediatric Solid Tumor Participants

Source: https://onco.cc/trials/nct07724756/  
OnCo record `nct07724756` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Albipagrastim alf in childhood cancers, run by Qilu Pharmaceutical Co., Ltd., now recruiting.

## Summary

Phase II Study of QLC2519 in Pediatric Solid Tumor Participants is a phase 2 interventional study registered as NCT07724756 by Qilu Pharmaceutical Co., Ltd., with 18 participants planned, started 2026-06-26 and due to reach its primary completion in 2027-06-26. Interventions recorded: Albipagrastim alf.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07724756
- Phase: 2
- Setting: A Multicenter, Open-label Phase II Clinical Study Evaluating the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of Albipagrastim Alfa for Injection (QLC2519) in Pediatric Solid Tumor Participants
- Sponsor: Qilu Pharmaceutical Co., Ltd.
- Enrolled: 18

## Sources

- ClinicalTrials.gov NCT07724756: https://clinicaltrials.gov/study/NCT07724756

## Connected records

- cancers: [Childhood cancers (all types)](https://onco.cc/cancers/childhood-cancers/)
- companies: [Qilu Pharmaceutical](https://onco.cc/companies/qilu-pharmaceutical/)

---
JSON: https://onco.cc/api/v1/entities/nct07724756.json